The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.